MTOR and B-cell chronic lymphocytic leukemia: Also, it has been demonstrated that MVs circulating in the plasma of B-cell chronic lymphocytic leukemia (CLL) patients can activate the AKT/mammalian target of rapamycin/p70S6K/hypoxia-inducible factor-1α axis in CLL BMSCs with the production of vascular endothelial growth factor, a survival factor for CLL B cells (28).